CNS Pharmaceuticals acquires Orphan Drug Designation for TPI 287

CNS Pharmaceuticals (CNSP) announced the successful transfer from Cortice Biosciences of Orphan Drug Designation for TPI 287. The U.S. Food and Drug Administration previously granted Orphan Drug Designations for TPI 287 in treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. Additionally, the Company announced the release of a “What This Means” segment to discuss the Orphan Drug Designations for TPI 287. TPI 287 is an abeotaxane with the same mechanism of action as other taxanes, such as paclitaxel and docetaxel; it stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. Although most taxanes are substrates for multi-drug resistant transporters that maintain the blood brain barrier, TPI 287’s clinical data suggest it has the potential to cross the BBB and treat CNS tumors. In a Phase 1 trial treating glioblastoma patients with TPI 287 in combination with bevacizumab, data include 3 Complete Responses and 9 Partial Responses out of 23 patients evaluable.